MAM
Behrouz Biryani spices up Ramzan 2026 Iftar menu
Badshahi & Nawabi Iftar boxes plus a-la-carte haleem and sheer khurma roll out for the holy month.
MUMBAI: When the sun sets and the call to break fast echoes, Behrouz Biryani is ready to turn Iftar into a royal affair – one slow-cooked spoonful at a time. As Ramzan 2026 begins, the brand is refreshing its much-loved offerings with limited-time Iftar boxes, timeless favourites and a multi-format campaign that keeps tradition simmering while honouring the month’s spirit of patience and togetherness.
Leading the lineup are two grand Iftar boxes. The Badshahi Iftari Sandooq serves a lavish 7-course feast for 3–4 people: Royal Dates, choice of Royal Biryani, Royal Gosht Haleem with Kulcha, Zareen Murgh Shorba, Murgh Patti Samosa, Murgh Koobideh Kebabs, Phirni, Sheer Khurma, Gulrosh Soda Sharbat and a Luxe Choco Indulgence gift box. For smaller gatherings of 1–2, the Nawabi Iftari Khazana offers a refined 5-course spread with Royal Dates, Royal Biryani, Gosht Haleem with Kulcha, Phirni and Gulrosh Soda Sharbat. Customers can pick their preferred biryani variant in both.
Beyond the boxes, the a-la-carte Ramzan menu brings back crowd-pleasers, Gosht Haleem, Murgh Haleem, Zareen Murgh Shorba, Sheer Khurma, Murgh Patti Samosa, Phirni, Gulrosh Soda Sharbat, Royal Dates and a seasonal Rose Falooda. The Luxe Choco Indulgence box doubles as a festive gifting option.
The storytelling ramps up with two hero films. One, narrated by Vijay Raaz, dives into Behrouz’s royal roots, dum pukht technique, long-grain basmati and its signature 23-shahi-masala blend. The other spotlights the slow, patient craft behind Behrouz Haleem, framing it as the comforting reward after a day of fasting. A Mushaira series in collaboration with Tape A Tale, plus influencer-led stories of families sharing Iftar across India, keeps the cultural conversation flowing.
Rebel Foods chief marketing officer Nishant Kedia captured the ethos: “Ramzan is a deeply significant period for our consumers, rooted in patience, gratitude, and togetherness. At Behrouz, we approach the month with great respect for these traditions. Our Ramzan menu from slow-cooked haleem to thoughtfully curated Iftar boxes is crafted to remain consistent, comforting, and deeply satisfying, strengthening the trust our consumers place in us.”
In a month where food becomes more than fuel, Behrouz isn’t just serving biryani, it’s dishing out memories, one fragrant layer at a time. Whether you’re breaking fast solo or with a full table, these offerings promise to make the evening feel a little more regal.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
